[go: up one dir, main page]

CN103554265A - Solid-phase synthesis method for gonadotropin-releasing hormone (GnRH) castration vaccine - Google Patents

Solid-phase synthesis method for gonadotropin-releasing hormone (GnRH) castration vaccine Download PDF

Info

Publication number
CN103554265A
CN103554265A CN201310557715.2A CN201310557715A CN103554265A CN 103554265 A CN103554265 A CN 103554265A CN 201310557715 A CN201310557715 A CN 201310557715A CN 103554265 A CN103554265 A CN 103554265A
Authority
CN
China
Prior art keywords
gnrh
lys
coupling
vaccine
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310557715.2A
Other languages
Chinese (zh)
Other versions
CN103554265B (en
Inventor
沙乐
崔贞亮
孙慕懿
顾声隆
胡成良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo Sansheng Biotechnology Co.,Ltd.
Original Assignee
NINGBO SANSHENG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NINGBO SANSHENG PHARMACEUTICAL CO Ltd filed Critical NINGBO SANSHENG PHARMACEUTICAL CO Ltd
Priority to CN201310557715.2A priority Critical patent/CN103554265B/en
Publication of CN103554265A publication Critical patent/CN103554265A/en
Application granted granted Critical
Publication of CN103554265B publication Critical patent/CN103554265B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a method for preparing a gonadotropin-releasing hormone (GnRH) parallel body and a vaccine in solid-phase conditions. After Lys is coupled on carrier resin, rink amide liners are respectively coupled on the two side chains of the Lys, and two same peptide chains are synthesized simultaneously. Disulfide bond bridging is realized on a solid phase, full-protective oxidation is adopted, and a large amount of impurities caused by the reaction involved by the side chains in the process are avoided.

Description

The method of solid phase synthesis GnRH castration vaccine
Technical field
The present invention relates to a kind of polypeptide synthesis method, relate in particular to a kind of solid phase synthesis for the synthetic method of the polypeptide of GnRH castration vaccine.
Background technology
For centuries, except planting with male animal, the male animal of most of domestic animals adopts operation castration always, the feed loss causing because of sexuality at fattening stage to reduce animal, reduce and to oestrus and that the Aggression of buck causes is injured and dead, and can improve the quality (as smell of mutton, peculiar smell alleviate) of meat, can also utilize the growth characteristic of castrated animal to make its getting fat.Therefore, castration is that domestic animal is fattened the important technical links in production process.
Yet after the advantage of self-discovery castration, in herding production, castration technology used is operation castration, very large to Animal stress, generally needs within 7-10 days, could recover, and sometimes can cause animal dead because of wound infection always.In addition, to the modus operandi castration of jenny, not only infection risk is larger, and operator's technology and muscle power are all had to very high requirement.In addition,, in a lot of countries and regions, the radical in animal welfare exerts pressure to prevent the castration of performing the operation always.
A kind of selection of alternative operation method of emasculation is to adopt the inoculation of GnRH castration vaccine, eliminate GnRF (GnRH, also referred to as LHRH) impact in vivo, make the animal body can not sexual maturity, can access better feed efficiency, compare safe ready simultaneously with operation castration, reduce infection chance, and partly retain the hormesis of sexual gland to breeding performonce fo animals.The antigen general formula of GnRH castration vaccine is as follows:
Z 1-Glx-His-Trp 1-Ser-Tyr-Gly-Leu-Arg-Pro-(Gly-X-Gln-His-Trp 2-Ser-Tyr-Gly-Leu-Arg-Pro) n-Gly-Z
Wherein, Trp 1and Trp 2be respectively tryptophane or formylation tryptophane (N-indoles-formyl radical-tryptophane); X is direct connecting key or Gly, Gln; Z 1-Glx is pGlu or the Glu that connects additional amino acid; Glx-Z 1for Gly-NH 2or the Gly of connection additional amino acid.
In the research of early stage GnRH vaccine, adopt GnRH monomer, immune consumption is large, needs multiple injection more, and US4608251 adopts body immunity arranged side by side, and result shows that immunogenicity is higher than monomer, better effects if.US6284733B1 carries out dimerization by GnRH body arranged side by side, forms dipolymer; Sequence is:
Figure BDA0000412036420000021
Wherein, * can be the amino acid such as Gly or D-Lys, D-Glu.Result of study shows, the immune castration vaccine that GnRH body dipolymer arranged side by side is basic structure is very effective.
In the preparation method of the disclosed described body arranged side by side of above-mentioned patent, the monomer of solid phase synthesis castration vaccine body arranged side by side before this, then by high performance liquid phase technology of preparing, prepare high-purity monomer, finally high-purity monomer is dissolved, under liquid-phase reaction condition, between Cys, connect and obtain body arranged side by side, then high performance liquid chromatography is purified.This method is also the current the most frequently used method of preparing GnRH body arranged side by side.
But in the disclosed preparation method of above-mentioned patent, in the end, in the process of synthetic body arranged side by side, side chain is easy to participate in reaction, thereby introduces a large amount of impurity, for purifying work afterwards brings very large difficulty.
Summary of the invention
For prior art, prepare that foreign matter content in body process arranged side by side is high, the problem of poor product quality, the invention provides the method for a kind of solid phase synthesis GnRH body arranged side by side.
First aspect of the present invention is to provide the method for a kind of solid phase synthesis GnRH body arranged side by side, and step comprises:
Step 1 connects Lys amino acid on solid-phase synthetic peptide vector resin (supporting resin), distinguishes coupling rink amide linker on two side chains of Lys, obtains the intermediate (A) of following structure:
Figure BDA0000412036420000022
Step 2, successively after the one or more amino acid of coupling, coupling Cys amino acid, or direct coupling Cys amino acid in other amino acid whose situation of not coupling, obtain the intermediate (B) of following structure:
Figure BDA0000412036420000023
Wherein, PG is side chain protected group; Z is one or more amino acid or connecting key, and wherein, Z is in amino acid whose situation, can be with or without side chain protected group, more preferably, and the amino acid that Z is non-Cys;
Step 3, then according to required synthetic GnRH body peptide chain structure arranged side by side successively other amino acid of coupling, obtains the intermediate (C) of following structure:
Wherein, peptide is peptide chain;
Step 4, utilizes two amino acid whose sulfydryls of Cys shown in intermediate (C), and between two Cys positions, formation-S-S-link, obtains intermediate (D);
Figure BDA0000412036420000032
But should be noted that, formation-S-S-link between two Cys positions shown in intermediate (C) of the present invention, can be to form between two peptide chains in same intermediate (C), can be also to form between the peptide chain between different intermediates (C);
Step 5, removes Side chain protective group, and makes polypeptide separated with vector resin, obtains GnRH body arranged side by side (E):
Figure BDA0000412036420000033
In the method described in the present invention is aspect first, Z is preferably the sequence that 1-4 amino acid forms, and 1-2 amino acid more preferably, as the sequence of Gly or Lys or the two composition, more preferably Lys.
In the method described in the present invention is aspect first, in described one or more coupling process, be preferably under condensing agent exists and carry out, described condensing agent can be to can be used in arbitrarily the condensing agent that promotes carboxylic acid and amine condensation, as any one or a few the combination in carbodiimide class condensing agent, salt condensing agent, organic phosphates condensing agent and other condensing agent etc.Wherein:
Carbodiimide class condensing agent is as dicyclohexylcarbodiimide (DCC), DIC (DIC), 1-(3-dimethylamino-propyl)-3-ethyl carbodiimide (EDCI) etc.;
Salt condensing agent is as O-(7-azepine benzotriazole-1-yl)-bis-(dimethylin) carbon hexafluorophosphate (HATU), O-(benzotriazole-1-yl)-bis-(dimethylin) carbon hexafluorophosphate (HBTU), O-(5-Chloro-Benzotriazole-1-yl)-bis-(dimethylin) carbon hexafluorophosphate HCTU, O-(7-azepine benzotriazole-1-yl)-bis-(Pyrrolidine base) carbon hexafluorophosphates (HAPyU), O-(benzotriazole-1-yl)-bis-(Pyrrolidine base) carbon hexafluorophosphates (HBPyU), O-(benzotriazole-1-yl)-bis-(dimethylin) carbon a tetrafluoro borate (TBTU), O-(N-succimide base)-bis-(dimethylin) carbon a tetrafluoro borate (TSTU), (down alkene-2 fall to O-in N-endo-5-, 3-bis-carbon imide bases)-bis-(dimethylin) carbon a tetrafluoro borate (TNTU), benzotriazole-1-base oxygen-tri-(dimethylin) Phosphonium hexafluorophosphate (BOP), benzotriazole-1-base oxygen-tri-(Pyrrolidine base) Phosphonium hexafluorophosphate (PyBOP), 7-azepine benzotriazole-1-base oxygen-tri-(Pyrrolidine base) Phosphonium hexafluorophosphate PyAOP etc.,
Organic phosphates condensing agent is as diphenyl phosphoryl chloride (DPP-Cl), diethyl cyanophosphonate (DECP), azide diphenyl phosphate (DPPA), sulfo-solutions of dimethyl phosphoryl base nitrine (MPTA), two (2-oxygen-3-oxazolidinyl) phosphoryl chloride (BOP-Cl) etc.;
Other condensing agent is as triphenyl phosphorus-many methyl halides, triphenyl phosphorus-hexachloroacetone, triphenyl phosphorus-NBS(NBS:N-bromo-succinimide) etc.
Wherein, in described one or more coupling process, can also add activator, the activator that can be used for carbodiimide class condensing agent comprises 4-N, N-lutidine (DMAP), 4-pyrrolidyl pyridine (4-PPY), 1-hydroxy benzo triazole (HOBt), 1-hydroxyl-7-azo benzotriazole (HOAt), (N-hydroxy-succinamide) HOSu, HP (NHPI), N-hydroxyl-5-norbornylene-2, the combination of any one or a few in 3-dicarboximide NHNI, Pentafluorophenol (PFPOH).
Wherein, in described one or more coupling process, can also add alkaline matter, can be organic bases and/or mineral alkali, organic bases more preferably, and described mineral alkali is as NaHCO 3, Na 2cO 3, NaOH, K 2cO 3, KOH, KH 2pO 4deng, described organic bases is preferably organic amine material, as triethylamine, N-methylmorpholine (NMM), diisopropylethylamine (DIEA) etc.
In the method described in the present invention is aspect first, step 1 connects the amino acid whose method of Lys and is preferably: Fmoc-Lys (Boc)-OH is connected on vector resin, and then deprotection group, obtains NH 2-Lys-supporting resin.
In the method described in the present invention is aspect first, the method for step 1 coupling rink amide linker is preferably: under DIC+NMM+HOBT exists, and Fmoc-rink amide linker and NH 2-Lys-supporting resin reaction, then deprotection base Fmoc obtains intermediate (A).
In the method described in the present invention is aspect first, in intermediate A the one or more amino acid of coupling, Cys amino acid and in intermediate B other amino acid whose method of coupling can be any one coupling method that adopts existing solid-phase synthetic peptide.
In the method described in the present invention is aspect first, the concept of described Side chain protective group, purposes and selection are all well-known to those skilled in the art.
In the method described in the present invention is aspect first, described vector resin can be arbitrarily for the resin of solid-phase synthetic peptide, can be the derivative of vinylbenzene-benzene divinyl cross-linked resin, polyacrylamide, polyethylene-ethylene glycol resin and above-mentioned resin; As PAM, MBHA, Merrifield, Wang(king's resin), 2-Cl-Trt etc., the present invention is preferably mbha resin.
In the situation that described vector resin is mbha resin, in step 5, the separated of deprotection base and resin can synchronously carry out.Preferably, step 5 is implemented under strong acidic condition.
Wherein, described strong acid is preferably trifluoroacetic acid (TFA).
More preferably, step 5 is implemented under TFA+ tri isopropyl silane (TIS) exists.
In method described in first aspect of the present invention, step 4 is preferably take iodine and reacts as oxygenant.
More preferably, the operation steps of step 4 comprises: in ice-water bath, and I 2join in intermediate (C) methanol solution and react.Reaction times is preferably 30min.
Wherein, described I 2the form being preferably with solution adds, more preferably I 2methanol solution, its concentration is preferably 0.5-2mol/L, more preferably 1-1.5mol/L.
In method described in first aspect of the present invention, can also comprise step 6, by prepared GnRH body freeze-drying arranged side by side.
In method described in first aspect of the present invention, described GnRH body peptide chain structure arranged side by side is preferably any one or a few the mixture with following structure.
p-Glu-His-Trp-Ser-Tyr-*-Leu-Arg-Pro-(&-X-Gln-His-Trp-Ser-Tyr-#-Leu-Arg-Pro)? n-Gly-Cys-Z-NH 2
Wherein, the integer that n is >=0, is preferably 0-2, and more preferably 1;
Wherein, Z is one or more amino acid, and is preferably Gly or Lys, more preferably Lys;
Wherein, X is Gly or Gln or connecting key;
Wherein, * and # can be identical or different, and are independently respectively any one D-amino acid or Gly; Wherein, described D-amino acid is preferably any one or a few in D-Ala, D-Lys, D-Glu, D-Orn; Wherein, & is Gly or Lys.
Second aspect of the present invention is to provide a kind of method of the GnRH of preparation castration vaccine, and step comprises:
Step 1, prepares GnRH body arranged side by side according to the method described in first aspect of the present invention;
Step 2, carries out coupling by described GnRH body arranged side by side and carrier proteins, is dissolved in solvent and makes GnRH vaccine.
In method described in aspect second of the present invention, in made GnRH vaccine, can also add immunological adjuvant.
Synthetic method provided by the invention, an amino acid of coupling (as Lys) on vector resin, then coupling rink amide linker on two side chains respectively, has realized two peptide chains simultaneously synthetic.
Disulfide linkage is oxidized formation on solid phase carrier; than traditional liquid phase oxidation technique; what the present invention adopted is full guard oxidation; other amino acid whose side chain in peptide sequence; in sulfydryl bridging process; all in protected state, avoided amino acid side chain in traditional method to participate in a large amount of impurity that reaction brings, for next step purifying work brings very big facility.
At MBHA as vector resin in the situation that; the present invention can also utilize the distinctive acid acceptance of MBHA; the summit that can realize peptide chain discharges, and cracking under the strong acid conditions such as TFA can and realize the cracking of synchronizeing of polypeptide and the separated of resin and amino acid side chain protecting group simultaneously.
Should be understood that, term in the present invention " amino acid " also comprises the amino-acid residue after being connected on peptide chain, and this is apparent for those skilled in the art.
Therefore, compare with traditional technology, synthetic method craft of the present invention quality more simple, the thick product of gained is significantly improved, and is conducive to subsequent purification, contributes to isolate high-quality antigenic peptide.
Accompanying drawing explanation
Fig. 1 is in the synthetic GnRH body method arranged side by side of the present invention, synchronously realizes the schematic diagram of polypeptide and amino acid side chain protecting group cracking separated with resin fixed point; Wherein PG is amino acid side chain protecting group;
Fig. 2 is body TOF-MS mass spectrometric detection result arranged side by side synthetic in the embodiment of the present invention 1;
Fig. 3 is body TOF-MS mass spectrometric detection result arranged side by side synthetic in the embodiment of the present invention 2;
Fig. 4 is body TOF-MS mass spectrometric detection result arranged side by side synthetic in the embodiment of the present invention 3.
Embodiment
Embodiment 1
In the present embodiment, GnRH peptide chain is: p-Glu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-Gln-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-Cys-Lys-NH 2.
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
Figure 20131055771521000021
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, more than methylene dichloride swelling 3h, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Method is: the Fmoc-Lys of 3eq (Fmoc)-OH and the DIC of 3eq HOBT and 3eq and the NMM of 1.5eq react, and reaction solvent is dry DMF, reaction times 1.5h.
Under 20% piperidines and DMF exist, remove the protecting group Fmoc of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, difference coupling Fmoc-rink amide linker on two side chains of Lys, method is: the Fmoc-Rink amid linker-OH of 6eq and the DIC of 6eqHOBT and 6eq and the NMM of 3eq react, reaction solvent is dry DMF, reaction times 1.5h.
Then remove protecting group, obtain:
Figure BDA0000412036420000081
Then adopting uses the same method carries out linked reaction with Fmoc-Lys (BOC)-OH, removes Fmoc protecting group, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains.Obtain the polypeptide of coupling resin.
Coupling is had in the polypeptide of resin and add methyl alcohol, under ice-water bath condition, stir 30min, drip the I of 1mol/L 2/ EtOH solution, until reaction system becomes brown color, continues to stir, if brown color disappears, continues to drip I 2/ EtOH solution.After reinforced complete reaction 30min, with in 10% (v/v) Sulfothiorine with excessive I 2.Ether and methanol wash, then vacuum-drying.
Under 95% (v/v) TFA+2.5% (v/v) water+2.5% (v/v) TIS exists; under 25-30 ℃ of condition, react 3h and carry out cracking, make polypeptide separated with resin fixed point, with this understanding; can also realize the synchronous cracking of amino acid side chain protecting group, as shown in Figure 1 simultaneously.
The lysate obtaining after the cracking of Ether precipitation, centrifugal, abandoning supernatant, washing, repeatable operation 2-3 time, throw out is fully dry under vacuum condition.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
Fig. 2 has provided the TOF-MS mass spectrometric detection result of the synthetic body arranged side by side of the present embodiment, and spectrogram result is consistent with the present embodiment object product.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Make the solution of 400 μ g/ml.
Fully emulsified with French 206 immunological adjuvant equal-volumes, make vaccine.
Embodiment 2
In the present embodiment, GnRH peptide chain is:
p-Glu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Lys-Gln-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Lys-Cys-Gly-NH 2
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Under 20% piperidines and DMF exist, remove the protecting group of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, on two side chains of Lys, difference coupling Fmoc-rink amide linker, then removes protecting group, obtains:
Figure BDA0000412036420000091
Coupling Gly and Cys, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains successively.
Iodine is catalyzer, carries out oxidizing reaction and between the Cys of two peptide chains amino acid, realizes disulfide linkage bridging.
There is lower cracking in TFA+EDT+Thioanisole, makes polypeptide separated with resin fixed point, with this understanding, can also realize the synchronous cracking of amino acid side chain protecting group simultaneously.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
The synthetic GnRH physique spectrogram arranged side by side of the present embodiment as shown in Figure 3.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Make the solution of 400 μ g/ml.
Fully emulsified with French 206 immunological adjuvant equal-volumes, make vaccine.
Embodiment 3
In the present embodiment, GnRH peptide chain is:
p-Glu-His-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-Gln-His-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-Cys-Gly-NH 2
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Under 20% piperidines and DMF exist, remove the protecting group of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, on two side chains of Lys, difference coupling Fmoc-rink amide linker, then removes protecting group, obtains:
Figure BDA0000412036420000101
Coupling Gly and Cys, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains successively.
Iodine is catalyzer, carries out oxidizing reaction and between the Cys of two peptide chains amino acid, realizes disulfide linkage bridging.
TFA+H 2there is lower cracking in O+Thioanisole, makes polypeptide separated with resin fixed point, with this understanding, can also realize the synchronous cracking of amino acid side chain protecting group simultaneously.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
The synthetic GnRH physique spectrogram arranged side by side of the present embodiment as shown in Figure 4.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Product is dissolved in the DEAE-dextran solution of 5% mass concentration, makes the pharmaceutical solutions of 400 μ g/ml.
Embodiment 4
In the present embodiment, GnRH peptide chain is:
p-Glu-His-Trp-Ser-Tyr-D-Orn-Leu-Arg-Pro-Gly-Gln-His-Trp-Ser-Tyr-D-Orn-Leu-Arg-Pro-Gly-Cys-Lys-NH 2
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Under 20% piperidines and DMF exist, remove the protecting group of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, on two side chains of Lys, difference coupling Fmoc-rink amide linker, then removes protecting group, obtains:
Figure BDA0000412036420000111
Coupling Lys and Cys, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains successively.
Iodine is catalyzer, carries out oxidizing reaction and between the Cys of two peptide chains amino acid, realizes disulfide linkage bridging.
There is lower cracking in TFA+EDT+Thioanisole, makes polypeptide separated with resin fixed point, with this understanding, can also realize the synchronous cracking of amino acid side chain protecting group simultaneously.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Product is dissolved in the DEAE-dextran solution of 5% mass concentration, makes the pharmaceutical solutions of 400 μ g/ml.
Embodiment 5
In the present embodiment, GnRH peptide chain is:
p-Glu-His-Trp-Ser-Tyr-D-Glu-Leu-Arg-Pro-Gly-Gln-His-Trp-Ser-Tyr-D-Glu-Leu-Arg-Pro-Gly-Cys-Gly-NH 2
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Under 20% piperidines and DMF exist, remove the protecting group of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, on two side chains of Lys, difference coupling Fmoc-rink amide linker, then removes protecting group, obtains:
Figure BDA0000412036420000112
Coupling Gly and Cys, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains successively.
Iodine is catalyzer, carries out oxidizing reaction and between the Cys of two peptide chains amino acid, realizes disulfide linkage bridging.
There is lower cracking in TFA+EDT+Thioanisole, makes polypeptide separated with resin fixed point, with this understanding, can also realize the synchronous cracking of amino acid side chain protecting group simultaneously.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Product is dissolved in the DEAE-dextran solution of 5% mass concentration, makes the pharmaceutical solutions of 400 μ g/ml.
Embodiment 6
In the present embodiment, GnRH peptide chain is:
p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Cys-NH 2
The present embodiment GnRH body arranged side by side and vaccine synthetic method are as follows:
synthetic GnRH body arranged side by side
Take mbha resin as vector resin, carry out linked reaction with Fmoc-Lys (BOC)-OH, Lys is coupled on mbha resin, obtain Fmoc-Lys (BOC)-MBHA Resin.Under 20% piperidines and DMF exist, remove the protecting group of Lys, obtain NH 2-Lys-MBHA Resin.
Under catalyzer and coupling agent DIC+NMM+HOBT existence, on two side chains of Lys, difference coupling Fmoc-rink amide linker, then removes protecting group, obtains:
Figure BDA0000412036420000121
Coupling Gys, then according to the above-mentioned peptide chain structure of the present embodiment successively other amino acid of coupling, synthetic when realizing two peptide chains.
Iodine is catalyzer, carries out oxidizing reaction and between the Cys of two peptide chains amino acid, realizes disulfide linkage bridging.There is lower cracking in TFA+EDT+Thioanisole, makes polypeptide separated with resin fixed point, with this understanding, can also realize the synchronous cracking of amino acid side chain protecting group simultaneously.
Preparative high performance liquid chromatography instrument is purified, and collects purity higher than 95% product, freeze-drying.
the preparation of GnRH vaccine
GnRH liquid solution arranged side by side joins in carrier proteins solution, adds coupling agent to carry out coupling.Make the solution of 400 μ g/ml.
Fully emulsified with French 206 immunological adjuvant equal-volumes, make vaccine.
GnRH castration vaccine prepared by the method for the invention, twice of immunity, can effectively excite GnRH antibody to produce, in and body in endogenous GnRH, thereby significantly reduce the size of testis, and reduce the sex hormone levels such as testosterone, reach the object of gentle castration, the weight loss that the castration that prevents from performing the operation causes is hemorrhage, infect and stress cause.
The GnRH castration vaccine that uses the present invention to prepare carries out after immunity, and with respect to the boar of operation castration, the speed of growth is very fast, and after butchering, on trunk, the eye muscle area at same position is obviously larger, and fat thickness is obviously thinner; With respect to uncastrated boar, the speed of growth is basically identical, and the quality of meat is good, there is no the distinctive shy taste of boar.
Above specific embodiments of the invention be have been described in detail, but it is just as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and alternative also all among category of the present invention.Therefore, equalization conversion and the modification done without departing from the spirit and scope of the invention, all should contain within the scope of the invention.

Claims (10)

1.一种固相合成GnRH并列体的方法,其特征在于,步骤包括:1. A method for solid-phase synthesis of GnRH juxtapositions, characterized in that the steps comprise: 步骤1,在固相合成多肽载体树脂上连接Lys氨基酸,在Lys两个侧链上分别偶联rink amide linker,得到如下结构的中间体(A):Step 1, linking Lys amino acid on the solid-phase synthetic polypeptide carrier resin, coupling rink amide linker on the two side chains of Lys respectively, to obtain the intermediate (A) with the following structure:
Figure FDA0000412036410000011
Figure FDA0000412036410000011
步骤2,依次偶联一个或多个氨基酸后,偶联Cys氨基酸,或者不偶联其它氨基酸的情况下直接偶联Cys氨基酸,得到如下结构的中间体(B):Step 2: After coupling one or more amino acids in sequence, couple Cys amino acids, or directly couple Cys amino acids without coupling other amino acids, to obtain an intermediate (B) with the following structure:
Figure FDA0000412036410000012
Figure FDA0000412036410000012
其中,PG为侧链保护基团;Z为一个或多个氨基酸、或者连接键;Wherein, PG is a side chain protecting group; Z is one or more amino acids, or a link; 步骤3,然后根据所需合成的GnRH并列体肽链结构依次偶联其它氨基酸,得到如下结构的中间体(C):Step 3, and then sequentially couple other amino acids according to the desired synthesized GnRH concatenated peptide chain structure to obtain an intermediate (C) with the following structure:
Figure FDA0000412036410000013
Figure FDA0000412036410000013
其中,peptide为肽链;Wherein, peptide is a peptide chain; 步骤4,利用中间体(C)所示的两个Cys中的巯基,在Cys之间形成-S-S-链接,得到中间体(D);Step 4, using the sulfhydryl groups in the two Cys shown in the intermediate (C) to form an -S-S- link between the Cys to obtain the intermediate (D);
Figure FDA0000412036410000014
Figure FDA0000412036410000014
步骤5,去除侧链保护基,并使多肽与载体树脂分离,得到GnRH并列体(E):Step 5, remove the side chain protecting group, and separate the polypeptide from the carrier resin to obtain the GnRH parallel body (E):
Figure FDA0000412036410000015
Figure FDA0000412036410000015
2.根据权利要求1所述的方法,其特征在于,Z为1-4个氨基酸组成的序列。2. The method according to claim 1, characterized in that Z is a sequence consisting of 1-4 amino acids. 3.根据权利要求2所述的方法,其特征在于,Z为Gly或Lys、或是二者组成的序列。3. The method according to claim 2, characterized in that Z is Gly or Lys, or a sequence consisting of both. 4.根据权利要求1所述的方法,其特征在于,所述载体树脂为MBHA树脂。4. The method according to claim 1, wherein the carrier resin is MBHA resin. 5.根据权利要求4所述的方法,其特征在于,步骤5中脱除保护基和树脂的过程,在强酸性条件下实施。5. The method according to claim 4, characterized in that, the process of removing protecting group and resin in step 5 is implemented under strongly acidic conditions. 6.根据权利要求1所述的方法,其特征在于,步骤4中所述形成-S-S-链接过程在碘存在下实施。6. The method according to claim 1, characterized in that, the process of forming the -S-S- link in step 4 is carried out in the presence of iodine. 7.根据权利要求6所述的方法,其特征在于,步骤4所述形成-S-S-链接过程在冰水浴条件下实施。7. The method according to claim 6, characterized in that the process of forming -S-S-linkage described in step 4 is carried out under ice-water bath conditions. 8.根据权利要求1所述的方法,其特征在于,还包括:8. The method of claim 1, further comprising: 步骤6,将所制备的GnRH并列体冻干。Step 6, freeze-drying the prepared GnRH juxtaposition. 9.一种制备GnRH去势疫苗的方法,其特征在于,步骤包括:9. A method for preparing GnRH castration vaccine, characterized in that the steps comprise: 步骤1,按照本发明第一个方面所述的方法制备GnRH并列体;Step 1, preparing a GnRH juxtaposition according to the method described in the first aspect of the present invention; 步骤2,将所述GnRH并列体与载体蛋白进行偶联,溶于溶剂中制成GnRH疫苗。In step 2, the GnRH juxtaposition is coupled with a carrier protein and dissolved in a solvent to prepare a GnRH vaccine. 10.根据权利要求9所述的制备GnRH去势疫苗的方法,其特征在于,所制成的GnRH疫苗中,还加入免疫佐剂。10. The method for preparing GnRH castration vaccine according to claim 9, characterized in that an immune adjuvant is also added to the prepared GnRH vaccine.
CN201310557715.2A 2013-11-11 2013-11-11 The method of the synthetic GnRH castration vaccine of solid phase Active CN103554265B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310557715.2A CN103554265B (en) 2013-11-11 2013-11-11 The method of the synthetic GnRH castration vaccine of solid phase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310557715.2A CN103554265B (en) 2013-11-11 2013-11-11 The method of the synthetic GnRH castration vaccine of solid phase

Publications (2)

Publication Number Publication Date
CN103554265A true CN103554265A (en) 2014-02-05
CN103554265B CN103554265B (en) 2016-05-04

Family

ID=50008650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310557715.2A Active CN103554265B (en) 2013-11-11 2013-11-11 The method of the synthetic GnRH castration vaccine of solid phase

Country Status (1)

Country Link
CN (1) CN103554265B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108047328A (en) * 2017-12-14 2018-05-18 天津瑞普生物技术股份有限公司 A kind of GnRH polypeptide antigens and its application for being used to prepare castration vaccine
CN110954706A (en) * 2019-11-20 2020-04-03 宁波三生生物科技有限公司 Method for measuring coupling rate of GnRH paralog dimer artificial antigen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284733B1 (en) * 1995-06-07 2001-09-04 Dlo Instituut Voor Dierhouderij En Diergezondheid Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
CN1455781A (en) * 2000-09-12 2003-11-12 Id-莱利斯塔德动物保健及动物育种研究所公司 Discrimination between GnRH-I and GnRH-II
US7361349B2 (en) * 1995-06-07 2008-04-22 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
CN102260321A (en) * 2011-04-02 2011-11-30 新加坡保健服务集团 Multimeric forms of antimicrobial peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284733B1 (en) * 1995-06-07 2001-09-04 Dlo Instituut Voor Dierhouderij En Diergezondheid Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
USRE39048E1 (en) * 1995-06-07 2006-03-28 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
US7361349B2 (en) * 1995-06-07 2008-04-22 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
CN1455781A (en) * 2000-09-12 2003-11-12 Id-莱利斯塔德动物保健及动物育种研究所公司 Discrimination between GnRH-I and GnRH-II
CN102260321A (en) * 2011-04-02 2011-11-30 新加坡保健服务集团 Multimeric forms of antimicrobial peptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108047328A (en) * 2017-12-14 2018-05-18 天津瑞普生物技术股份有限公司 A kind of GnRH polypeptide antigens and its application for being used to prepare castration vaccine
WO2019114123A1 (en) * 2017-12-14 2019-06-20 天津瑞普生物技术股份有限公司 Gnrh polypeptide antigen and use thereof for preparing castration vaccines
CN110954706A (en) * 2019-11-20 2020-04-03 宁波三生生物科技有限公司 Method for measuring coupling rate of GnRH paralog dimer artificial antigen
CN110954706B (en) * 2019-11-20 2020-10-02 宁波三生生物科技有限公司 Method for measuring coupling rate of GnRH paralog dimer artificial antigen

Also Published As

Publication number Publication date
CN103554265B (en) 2016-05-04

Similar Documents

Publication Publication Date Title
US7348404B2 (en) Solid-phase peptide synthesis and agent for use in such synthesis
US20190177392A1 (en) Synthesis of glp-1 peptides
DK2421887T3 (en) A process for the preparation of degarelix
CN119119238A (en) Method for preparing GIP/GLP1 dual agonist
CN106928313B (en) Synthesis method of C-terminal modified peptide
CN109195618A (en) Methods for synthesizing α4β7 peptide antagonists
CN104387454B (en) A kind of method that fragment condensation prepares Triptorelin
KR20170026326A (en) Method for preparing amg 416
CN102702327B (en) Solid-liquid phase synthesis method for alarelin acetate
US20130060004A1 (en) Novel Process For The Preparation Of Leuprolide And Its Pharmaceutically Acceptable Salts Thereof
WO2017097194A1 (en) Completely-solid-phase preparation method for carbetocin
CN105601718A (en) Solid-phase synthesis method of bremelanotide
CN107056894B (en) Method for solid-phase synthesis of ganirelix acetate by fragment method
CN104177478A (en) Method for synthesizing degarelix
TW201249862A (en) Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
CN103554265A (en) Solid-phase synthesis method for gonadotropin-releasing hormone (GnRH) castration vaccine
López-Macià et al. Kahalalide B. Synthesis of a natural cyclodepsipeptide
CN104017058B (en) A kind of method preparing ganirelix acetate
US7176282B1 (en) Solid-phase peptide synthesis and agent for use in such synthesis
CN103554228B (en) A kind of GnRH castration vaccine and side by side body
CN107778355B (en) Method for synthesizing cetrorelix
CN103554229A (en) Solid-phase synthesis method for Buserelin
JPH09501913A (en) N-terminal modified analogue of LHRH
Mathieu et al. Novel strategy for the synthesis of template‐assembled analogues of rat relaxin1 1
Szymanowska‐Dziubasik et al. Synthesis, cardiostimulatory, and cardioinhibitory effects of selected insect peptides on Tenebrio molitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171121

Address after: 315000 Bu Zheng Dong Road, Ningbo, Haishu District, Zhejiang Province, No. 159

Patentee after: Ningbo Sansheng Biological Technology Co., Ltd.

Address before: 315100 Zhejiang city of Ningbo province Yinzhou District River Street fire pan Industrial Zone, Spring Garden Road No. 68

Patentee before: Ningbo Sansheng Pharmaceutical Co., Ltd.

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: 159 Buzheng East Road, Wangchun Industrial Park, Haishu District, Ningbo City, Zhejiang Province, 315000

Patentee after: Ningbo Sansheng Biotechnology Co.,Ltd.

Address before: 159 Buzheng East Road, Wangchun Industrial Park, Haishu District, Ningbo City, Zhejiang Province, 315000

Patentee before: NINGBO SANSHENG BIOLOGICAL TECHNOLOGY Co.,Ltd.

CP01 Change in the name or title of a patent holder